Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients
Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients
复制标题
DOI：
10.1038/ajh.2008.29
复制
发表时间：
2008-06-01
影响因子：
3.2
通讯作者：
Fukagawa, Masafumi
中科院分区：
文献类型：
--
作者：
Fujii, Hideki;Takiuchi, Shin;Fukagawa, Masafumi
背景：尽管心脏和肾脏功能障碍经常同时出现，但这些病理生理过程之间的关系尚不清楚。不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮（NO）合成酶抑制剂，与内皮功能障碍和动脉粥样硬化有关。本研究阐明了ADMA与肾内及冠状动脉微血管疾病的关系。方法本研究纳入66例肾功能正常或轻度肾功能不全的连续高血压患者(肌酐= 90 ml/min；肾功能不全组，eGFR
BACKGROUND Despite the frequent simultaneous presentation of cardiac and renal dysfunction, the relationship between these pathophysiological processes remains unclear. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase, which has been linked to endothelial dysfunction and atherosclerosis. This study elucidates the relationship between ADMA and intrarenal and coronary microvascular diseases.METHODS In this study, we included 66 consecutive hypertensive patients with normal renal function or mild renal insufficiency (creatinine = 90 ml/min; renal insufficiency group, eGFR